U.K. biotech Nemaura Pharma reported securing funding commitments totalling £5 million ($6.2 million) from private investors to support the continued development of its Micro-Patch™ technology for ...
The Nemaura Medical (NASDAQ:NMRD) Share Price Is Down 63% So Some Shareholders Are Wishing They Sold
Nemaura Medical Inc. (NASDAQ:NMRD) shareholders should be happy to see the share price up 14% in the last week. But that's not enough to compensate for the decline over the last twelve months. Like a ...
Loughborough, UK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital ...
With their enhanced drug absorption and drug stability, Nemaura's easy-to-use transdermal technologies are expected to improve patient compliance and outcomes LONDON, Dec. 7, 2016 /PRNewswire/ -- ...
LOUGHBOROUGH, England--(BUSINESS WIRE)-- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic ...
LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use ...
LOUGHBOROUGH, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc (NMRD).(NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising ...
LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical Inc. (OTC BB: NMRD), ("Nemaura"), a medical device company developing the sugarBEAT ® CGM System as a minimally invasive, wireless continuous ...
Loughborough, England, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results